Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) Director of Life Scienced Mike Farber joined Steve Darling from Proactive with news the company has announced they are adding the South African Variant to their upcoming Bio Safety Level 4 lab study, which is analyzing viral clearance efficacy with the Company's Ivermectin technology.
Farber talks about why they thought this was an important step to take considering there is concern about the variant whether the vaccines are rendered less effective against the variant.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HERE
